The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-27

Study Completion Date

2017-12-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Delineation of the anatomical location, cellular origin and molecular basis of gut-derived glucagon secretion

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes

NCT00704795

Hyperglucagonemia Hyperglycemia Diabetes Mellitus

UNKNOWN

A Glucometabolic Evaluation of Patients With Idiopathic Ketotic Hypoglycemia

NCT05310292

Idiopathic Ketotic Hypoglycemia

UNKNOWN NA

Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion

NCT02010827

Type 2 Diabetes Mellitus

COMPLETED

The Effect of Insulin-induced Hypoglycaemia on Gut-derived Glucagon Secretion (Px-Hypo)

NCT04064203

Diabetes After Total Pancreatectomy

COMPLETED NA

Hepatic Metabolic Changes in Response to Glucagon Infusion

NCT03526445

Non-Alcoholic Fatty Liver Disease Total Pancreatectomy Diabetes Mellitus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim: to delineate the anatomical origin, the molecular structure and precursors, the regulation and the (patho-) physiological implications of gut-derived glucagon.

Eight totally pancreatectomised patients, eight type 2 diabetes patients and eight healthy controls (age 18-80, BMI \<30) with normal kidney and liver parameters and hgb\> 6.5 - will be included. The participants will each undergo one screening day and one study day including a gastroduodenoscopy. Multiple biopsies will be taken at several predefined locations in the upper gastrointestinal tract. These biopsies will be analysed with different techniques including immunohistochemical staining, quantitative polymerase chain reaction (qPCR-) analyses and more to search for glucagon. After the last biopsy has been collected, 50 g of glucose dissolved in 100 ml water is infused through the enteroscope into the most proximal part of the small intestine. Hereafter blood samples for glucagon and gut hormone analyses will be collected 15, 30 and 45 min after the glucose infusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glucose Metabolism Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.